Financial Comparison: QuidelOrtho (QDEL) versus Its Peers

QuidelOrtho (NASDAQ:QDEL) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its competitors? We will compare QuidelOrtho to related businesses based on the strength of its valuation, risk, dividends, analyst recommendations, earnings, profitability and institutional ownership.

Risk & Volatility

QuidelOrtho has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Comparatively, QuidelOrtho’s competitors have a beta of 2.57, suggesting that their average share price is 157% more volatile than the S&P 500.

Institutional & Insider Ownership

99.0% of QuidelOrtho shares are held by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 1.1% of QuidelOrtho shares are held by insiders. Comparatively, 14.8% of shares of all “Healthcare Equipment & Supplies” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings for QuidelOrtho and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
QuidelOrtho	2	4	0	0	1.67
QuidelOrtho Competitors	4266	10523	18283	825	2.46

QuidelOrtho currently has a consensus target price of $13.62, indicating a potential upside of 6.11%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 19.55%. Given QuidelOrtho’s competitors stronger consensus rating and higher possible upside, analysts clearly believe QuidelOrtho has less favorable growth aspects than its competitors.

Earnings and Valuation

This table compares QuidelOrtho and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
QuidelOrtho	$2.73 billion	-$1.13 billion	-0.83
QuidelOrtho Competitors	$1.91 billion	$138.76 million	9.37

QuidelOrtho has higher revenue, but lower earnings than its competitors. QuidelOrtho is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares QuidelOrtho and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
QuidelOrtho	-14.24%	3.22%	1.03%
QuidelOrtho Competitors	-276.78%	-149.08%	-21.73%

Summary

QuidelOrtho competitors beat QuidelOrtho on 8 of the 13 factors compared.

QuidelOrtho Company Profile

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.